These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 2693918

  • 1. Nandrolone decanoate treatment of post-menopausal osteoporosis for 2 years and effects of withdrawal.
    Hassager C, Riis BJ, Pødenphant J, Christiansen C.
    Maturitas; 1989 Dec; 11(4):305-17. PubMed ID: 2693918
    [Abstract] [Full Text] [Related]

  • 2. Effects of nandrolone decanoate therapy on bone mass and calcium metabolism in women with established post-menopausal osteoporosis: a double-blind placebo-controlled study.
    Gennari C, AgnusDei D, Gonnelli S, Nardi P.
    Maturitas; 1989 Sep; 11(3):187-97. PubMed ID: 2687645
    [Abstract] [Full Text] [Related]

  • 3. Nandrolone decanoate and intranasal calcitonin as therapy in established osteoporosis.
    Flicker L, Hopper JL, Larkins RG, Lichtenstein M, Buirski G, Wark JD.
    Osteoporos Int; 1997 Sep; 7(1):29-35. PubMed ID: 9102059
    [Abstract] [Full Text] [Related]

  • 4. Effects of nandrolone decanoate on bone mass in established osteoporosis.
    Passeri M, Pedrazzoni M, Pioli G, Butturini L, Ruys AH, Cortenraad MG.
    Maturitas; 1993 Nov; 17(3):211-9. PubMed ID: 8133796
    [Abstract] [Full Text] [Related]

  • 5. Double-blind placebo--controlled trial of nandrolone decanoate in postmenopausal osteoporosis.
    Chhaparwal M, Saraf ML.
    Indian J Med Sci; 1998 Jun; 52(6):236-8. PubMed ID: 9849033
    [No Abstract] [Full Text] [Related]

  • 6. Course of bone mass during and after hormonal replacement therapy with and without addition of nandrolone decanoate.
    Erdtsieck RJ, Pols HA, van Kuijk C, Birkenhäger-Frenkel DH, Zeelenberg J, Kooy PP, Mulder P, Birkenhäger JC.
    J Bone Miner Res; 1994 Feb; 9(2):277-83. PubMed ID: 8140941
    [Abstract] [Full Text] [Related]

  • 7. Effects of nandrolone decanoate (Decadurabolin) on serum Lp(a), lipids and lipoproteins in women with postmenopausal osteoporosis.
    Lippi G, Guidi G, Ruzzenente O, Braga V, Adami S.
    Scand J Clin Lab Invest; 1997 Oct; 57(6):507-11. PubMed ID: 9350070
    [Abstract] [Full Text] [Related]

  • 8. Treatment of postmenopausal osteoporosis: is the anabolic steroid nandrolone decanoate a candidate?
    Johansen JS, Hassager C, Pødenphant J, Riis BJ, Hartwell D, Thomsen K, Christiansen C.
    Bone Miner; 1989 Apr; 6(1):77-86. PubMed ID: 2665884
    [Abstract] [Full Text] [Related]

  • 9. Cross-over study of fat-corrected forearm mineral content during nandrolone decanoate therapy for osteoporosis.
    Need AG, Horowitz M, Walker CJ, Chatterton BE, Chapman IC, Nordin BE.
    Bone; 1989 Apr; 10(1):3-6. PubMed ID: 2736154
    [Abstract] [Full Text] [Related]

  • 10. Double-blind placebo-controlled trial of treatment of osteoporosis with the anabolic nandrolone decanoate.
    Need AG, Nordin BE, Chatterton BE.
    Osteoporos Int; 1993 Apr; 3 Suppl 1():218-22. PubMed ID: 8461566
    [No Abstract] [Full Text] [Related]

  • 11. Changes in soft tissue body composition and plasma lipid metabolism during nandrolone decanoate therapy in postmenopausal osteoporotic women.
    Hassager C, Pødenphant J, Riis BJ, Johansen JS, Jensen J, Christiansen C.
    Metabolism; 1989 Mar; 38(3):238-42. PubMed ID: 2645503
    [Abstract] [Full Text] [Related]

  • 12. The carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen in serum as a marker of bone resorption: the effect of nandrolone decanoate and hormone replacement therapy.
    Hassager C, Jensen LT, Pødenphant J, Thomsen K, Christiansen C.
    Calcif Tissue Int; 1994 Jan; 54(1):30-3. PubMed ID: 8118750
    [Abstract] [Full Text] [Related]

  • 13. Virilization of the voice in post-menopausal women due to the anabolic steroid nandrolone decanoate (Decadurabolin). The effects of medication for one year.
    Gerritsma EJ, Brocaar MP, Hakkesteegt MM, Birkenhäger JC.
    Clin Otolaryngol Allied Sci; 1994 Feb; 19(1):79-84. PubMed ID: 8174308
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The androgenic anabolic steroid nandrolone decanoate prevents osteopenia and inhibits bone turnover in ovariectomized cynomolgus monkeys.
    Jerome CP, Power RA, Obasanjo IO, Register TC, Guidry M, Carlson CS, Weaver DS.
    Bone; 1997 Apr; 20(4):355-64. PubMed ID: 9108356
    [Abstract] [Full Text] [Related]

  • 16. [Effects on the bones of nandrolone decanoate therapy in postmenopausal osteoporosis].
    Gennari C, Agnusdei D, Gonnelli S.
    Minerva Endocrinol; 1989 Apr; 14(1):69-74. PubMed ID: 2659955
    [Abstract] [Full Text] [Related]

  • 17. Effects of nandrolone therapy on forearm bone mineral content in osteoporosis.
    Need AG, Horowitz M, Morris HA, Walker CJ, Nordin BE.
    Clin Orthop Relat Res; 1987 Dec; (225):273-8. PubMed ID: 3677513
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Mechanical properties, bone mineral content, and bone composition (collagen, osteocalcin, IGF-I) of the rat femur: influence of ovariectomy and nandrolone decanoate (anabolic steroid) treatment.
    Aerssens J, Van Audekercke R, Geusens P, Schot LP, Osman AA, Dequeker J.
    Calcif Tissue Int; 1993 Oct; 53(4):269-77. PubMed ID: 8275356
    [Abstract] [Full Text] [Related]

  • 20. Bodybuilders' body composition: effect of nandrolone decanoate.
    van Marken Lichtenbelt WD, Hartgens F, Vollaard NB, Ebbing S, Kuipers H.
    Med Sci Sports Exerc; 2004 Mar; 36(3):484-9. PubMed ID: 15076791
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.